Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

As you might know, Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) just kicked off its latest second-quarter results ...

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Amicus Therapeutics Inc (FOLD) reports its 17th consecutive quarter of double-digit revenue growth, while navigating increased operating expenses and ongoing litigation challenges.

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...

Highlights,XTX Topco Ltd significantly increased its position in Amicus Therapeutics during the first quarter,Shares of ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $24.4 million in its second quarter. On a per-share basis, the Princeton, New Jersey-based ...

Amicus Therapeutics (FOLD) could be a solid choice for investors given the company's remarkably improving earnings outlook.

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July ...

Amicus Therapeutics (($FOLD)) has held its Q2 earnings call. Read on for the main highlights of the call. Amicus Therapeutics’ recent earnings ...

Investing.com - Morgan Stanley has upgraded Amicus Therapeutics (NASDAQ:FOLD) from Equalweight to Overweight with a price target of $12.00, citing the company’s strong intellectual property ...

With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases.